Last checked at 28 Dec 2017 07:00
For immediate release | 28 December 2017 |
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Completion of acquisition of Vamousse®
On 4 December 2017 Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announced that its wholly owned subsidiary, Alliance Pharmaceuticals Limited, had entered into an agreement to acquire the worldwide rights to Vamousse from TyraTech Inc (AIM: TYR and TYRU) (the "Acquisition").
Further to Tyratech's announcement on 27 December 2017 that its shareholders have approved the Acquisition, Alliance is pleased to announce that it has today completed the Acquisition.
Alliance is also pleased to announce the appointment of Amanda Sicvol as Country Manager for its newly created US affiliate. Amanda has been instrumental in the commercial success of Vamousse to date, having worked for Tyratech for four years. She brings significant expertise and considerable knowledge of the Vamousse brand.
John Dawson, Alliance Pharma's Chief Executive Officer, commented: "The completion of this acquisition provides Alliance a third International star brand with best in class technology. There is also real potential for further growth through our substantial global network of distributors. We are delighted to welcome Amanda to Alliance to establish our presence in the US, the largest consumer healthcare market in the world."
- Ends -
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 |
John Dawson, Chief Executive Officer Peter Butterfield, Deputy Chief Executive Officer Andrew Franklin, Chief Financial Officer | |
www.alliancepharma.co.uk | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Sophie Wills / Gemma Mostyn-Owen | |
Numis Securities Limited | + 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Freddie Barnfield | |
Corporate Broking: James Black / Toby Adcock | |
Investec Bank plc | +44 (0) 20 7597 5970 |
Corporate Finance: Daniel Adams / Ed Thomas Corporate Broking: Patrick Robb / Rob Baker
|
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international specialty pharmaceutical company based in Chippenham, Wiltshire, UK. The Group has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Group continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.